CG Oncology (CGON) announced that it has completed enrollment in its Phase 3, randomized, open-label PIVOT-006 study comparing adjuvant intravesical cretostimogene grenadenorepvec versus surveillance following bladder tumor removal in patients with intermediate-risk non-muscle invasive bladder cancer, IR NMIBC.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- CG Oncology initiated with an Overweight at Piper Sandler
- CG Oncology’s Strategic Advancements and Promising Data Reinforce Buy Rating
- CG Oncology price target lowered to $62 from $63 at BofA
- CG Oncology’s Q2 2025: Clinical Advances and Legal Wins
- Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements